Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Hospira exceeds expectations in first quarter of 2011

Hospira exceeds expectations in first quarter of 2011

27th April 2011

Hospira has been able to outperform its own internal business forecasts during the first quarter of the new fiscal year.

The company generated just over $1 billion (603.46 million pounds) during the three-month period, which was roughly level with last year's first quarter.

Strong US sales of the cancer therapies docetaxel and gemcitabine helped to contribute to this stronger-than-expected total, in addition to improved momentum for a number of existing and newly launched drugs.

Christopher Begley, Hospira's executive chairman and former chief executive officer (CEO), also highlighted the company's success in driving quality enhancements and decreasing back order levels.

Additionally, the company introduced F Michael Ball as its new CEO during the quarter, joining Hospira from his former role as Allergan president on March 28th 2011.

Mr Begley said: "After his first few weeks with us, I am even more confident he is the right person to lead the company and build on all we have accomplished over the past seven years."ADNFCR-8000103-ID-800512683-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.